Should Everyone Be On a GLP-1?

Semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) have taken the diabetes and weight-loss worlds by storm since their U.S. FDA approvals in 2017 and 2022, respectively.

The benefits on diabetes and weight loss were clear from the outset - but is there more to the story? Follow David S. Filippi, MD, your SIGNIFICANT podcast host, on a deep dive into the new data suggesting that there may be a myriad of deeper benefits to these medications - including some as yet unknown!

Are these drugs the most significant medications of the 21st century? You be the judge.